Chiasma Inc (CHMA) Stock Price & Overview
NASDAQ:CHMA
The current stock price of CHMA is 3.76 null. Today CHMA is down by -6%. In the past month the price decreased by -13.56%. In the past year, price decreased by -21.5%.
CHMA Key Statistics
- Market Cap
- 217.681M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.61
- Dividend Yield
- N/A
CHMA Stock Performance
CHMA Stock Chart
CHMA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CHMA. When comparing the yearly performance of all stocks, CHMA is a bad performer in the overall market: 90.21% of all stocks are doing better.
CHMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CHMA. CHMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CHMA Earnings
CHMA Forecast & Estimates
4 analysts have analysed CHMA and the average price target is 9.28 null. This implies a price increase of 146.86% is expected in the next year compared to the current price of 3.76.
For the next year, analysts expect an EPS growth of 12.13% and a revenue growth 1731.35% for CHMA
CHMA Groups
Sector & Classification
CHMA Financial Highlights
Over the last trailing twelve months CHMA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -46.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2968.35% | ||
| ROA | -56.38% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CHMA Ownership
CHMA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.85 | 934.238B | ||
| JNJ | JOHNSON & JOHNSON | 20.83 | 579.34B | ||
| MRK | MERCK & CO. INC. | 22.63 | 286.278B | ||
| PFE | PFIZER INC | 8.98 | 153.814B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.57 | 122.779B | ||
| ZTS | ZOETIS INC | 17.29 | 51.259B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.87 | 26.195B | ||
| VTRS | VIATRIS INC | 5.67 | 16.304B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.76 | 11.614B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.303B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.501B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.547B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.59 | 4.166B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CHMA
Company Profile
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Company Info
IPO: 2015-07-16
Chiasma Inc
140 Kendrick Street, Building C East
Needham MASSACHUSETTS 02494 US
CEO: Raj Kannan
Employees: 85
Phone: 16179285300.0
Chiasma Inc / CHMA FAQ
What does Chiasma Inc do?
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Can you provide the latest stock price for Chiasma Inc?
The current stock price of CHMA is 3.76 null. The price decreased by -6% in the last trading session.
What is the dividend status of Chiasma Inc?
CHMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHMA stock?
CHMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CHMA stock?
4 analysts have analysed CHMA and the average price target is 9.28 null. This implies a price increase of 146.86% is expected in the next year compared to the current price of 3.76.
Would investing in Chiasma Inc be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CHMA.